share_log

Citius Pharmaceuticals Executes Definitive Agreement To Merge Wholly Owned Subsidiary With TenX Keane Acquisition To Form Publicly Listed Citius Oncology, Inc.

Benzinga ·  Oct 24, 2023 07:35

Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment